Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions
| Status: | Completed |
|---|---|
| Conditions: | Arthritis, Chronic Obstructive Pulmonary Disease, Erectile Dysfunction, Osteoarthritis (OA), Cardiology, Infectious Disease, Neurology, Pulmonary |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Immunology / Infectious Diseases, Nephrology / Urology, Neurology, Pulmonary / Respiratory Diseases, Rheumatology |
| Healthy: | No |
| Age Range: | 16 - Any |
| Updated: | 9/27/2018 |
| Start Date: | September 2, 2013 |
| End Date: | January 1, 2017 |
Clinical Intervention Study: Adverse Events and Clinical Outcomes for the Deployment of Adipose Derived SVF (Rich in Adult Stem Cells and Growth Factors)for Select Orthopedic, Neurologic, Urologic, and Cardio-Pulmonary Conditions.
To evaluate for any adverse effects that may be related to the administration and reception
of autologous adipose derived stromal vascular fraction (SVF). Secondarily, the study
monitors the results of subjective and objective findings as it applies to the non-blinded
deployment of autologous SVF for various inflammatory and/or degenerative conditions
including select orthopedic, neurologic, urologic and cardio-pulmonary conditions. SVF
deployments include intra-venous, intra-articular, and soft tissue injections.
of autologous adipose derived stromal vascular fraction (SVF). Secondarily, the study
monitors the results of subjective and objective findings as it applies to the non-blinded
deployment of autologous SVF for various inflammatory and/or degenerative conditions
including select orthopedic, neurologic, urologic and cardio-pulmonary conditions. SVF
deployments include intra-venous, intra-articular, and soft tissue injections.
SVF Stromal Vascular Fraction is obtained by lipoharvesting, procurement, and lipo-transfer
as a same day operative procedure
as a same day operative procedure
Inclusion Criteria
- Patient must be age 16 or older
- Patient must have a degenerative disease or inflammatory disease that meets criteria
for treatment under the IRB which includes: Arthritis, Auto-immune disease,COPD,
Cardiomyopathy, Peyronies Disease,Interstitial Cystitis, Erectile Dysfunction, and
Neurodegenerative disease such as Parkinsons, ALS, Neuropathy.
- Patient must be healthy enough to tolerate a local anesthetic
Exclusion Criteria:
- Patient must not have active cancer
- Patient must not have active infection
We found this trial at
1
site
Rancho Mirage, California 92270
Principal Investigator: Mark H Berman, MD
Phone: 800-231-0407
Click here to add this to my saved trials
